title: [Fibrinolytic therapy].
abstract: Fibrinolytic therapy still is a keystone in the therapeutic approach of acute occlusion in different vascular regions. However, before starting fibrinolytic therapy an evidence-based risk assessment is necessary. This article presents the most common fibrinolytic agents as well as evidences and recommendations for fibrinolytic therapy of different vascular regions.
authors.affiliation: University Clinic "Carl Gustav Carus", Division of Vascular Medicine, Technical University Dresden.
authors.forename: J
authors.initials: J
authors.lastname: Beyer
authors.forename: S
authors.initials: S
authors.lastname: Schellong
mesh_terms: D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D010960:Plasminogen Activators / Q000235:genetics / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000379:methods*
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010960:Plasminogen Activators